belantamab mafodotin + lenalidomide + dexamethasone

This is a **combination regimen** used as therapy for multiple myeloma, composed of belantamab mafodotin, lenalidomide, and dexamethasone. - **Belantamab mafodotin:** a first-in-class antibody-drug conjugate (ADC), consisting of a humanized, afucosylated monoclonal antibody targeting B-cell maturation antigen (BCMA), conjugated to the microtubule inhibitor monomethyl auristatin F. Its mechanism involves binding to BCMA on myeloma cells, leading to direct cytotoxicity, immune-mediated cell death, and delivery of the cytotoxic payload. - **Lenalidomide:** a small molecule immunomodulatory agent (IMiD) that exerts antineoplastic effects via modulation of the cereblon E3 ubiquitin ligase complex, downregulation of key survival genes, and stimulation of anti-tumor immunity. - **Dexamethasone:** a glucocorticoid (corticosteroid) with anti-inflammatory and cytotoxic effects, widely used in myeloma as part of combination regimens. This triplet combination is under investigation as induction and first-line therapy in newly diagnosed, transplant-ineligible patients, as well as in relapsed/refractory multiple myeloma.[1][4][5][6][7]

Other names

belamaf + lenalidomide + dexamethasone